Clinical Trial

Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Dose.

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of two evolocumab drug products in healthy participants.
Protocol Amendment History 3 changes
critical Trial status changed: RECRUITING → ACTIVE_NOT_RECRUITING 2026-07-21
critical Recruitment opened 2026-07-02
notable Trial sites expanded: 0 -> 5 locations 2026-07-02
Trial Details
NCT Number NCT07545226
Lead Sponsor Amgen
Conditions Healthy Participants
Enrollment 405 participants
Start Date 2026-04-21
Primary Completion 2026-09-03 (estimated)
Study Completion 2026-09-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-20